Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1565-1571

  Tanios, Rita ^a   Bekdash, Amira ^a   Kassab, Elias ^a   Stone, Everett ^b   Georgiou, Georges ^b   Frankel, Arthur E ^c   Abi Habib, Ralph J ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AML; Arginine; Autophagy; HuArgI(Co) PEG5000

Indexed keywords

ARGININE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHASE 1; CITRULLINE; CYTARABINE; DOXORUBICIN; MACROGOL 5000; MACROGOL DERIVATIVE; PEGYLATED HUMAN RECOMBINANT ARGINASE I COBALT; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOPHAGY; AUXOTROPHY; BONE MARROW CELL; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AML; ARGININE; AUTOPHAGY; HUARGI(CO)-PEG5000;

APOPTOSIS; ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 84886786852     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.007     Document Type: Article

References (28)

1. American Cancer Society Cancer facts and figures 2012 2012, American Cancer Society, Atlanta, GA.
2. Bennett J.M., Kouides P.A., Forman S.J. The myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int J Hematol 2002, 2:228-238.
3. Stone E.M., Glazer E.S., Chantranupong L., Cherukuri P., Breece R.M., Tierney D.L., et al. Replacing Mn(2+) with Co(2+) in human arginase I enhances cytotoxicity towards l-arginine auxotrophic cancer cell line. ACS Chem Biol 2010, 5:333-342.
4. Morris S.M. Enzymes of arginine metabolism. J Nutr 2004, 134:2743S-2747S.
5. Kuo M.T., Savaraj N., Feun L.G. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 2010, 1:246-251.
6. Mussai F., De Santo C., Abu-Dayyeh I., Booth S., Quek L., McEwen-Smith R.M., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 2013, 122:749-758.
7. Muller H.J., Boos J. Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998, 28:97-113.
8. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005, 23:7660-7668.
9. Cheng P.N., Lam T.L., Lam W.M., Tsui S.M., Cheng A.W., Lo W.H., et al. Pegylated recombinant human arginase (rhArg-peg5000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007, 67:309-317.
10. Hernandez C.P., Morrow K., Lopez-Barcons L.A., Zabaleta J., Sierra R., Velasco C., et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 2010, 115:5214-5221.
11. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004, 2:1815-1822.
12. Lam T.L., Wong G.K., Chong H.C., Cheng P.N., Choi S.C., Chow T.L., et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 2009, 277:91-100.
13. Yoon C.Y., Shim Y.J., Kim E.H., Lee J.H., Won N.H., Kim J.H., et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007, 120:897-905.
14. Huang C.C., Tsai S.T., Kuo C.C., Chang J.S., Jin Y.T., Chang J.Y., et al. Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncol 2012, 48:1227-1235.
15. Glazer E.S., Stone E.M., Zhu C., Massey K.L., Hamir A.N., Curley S.A. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol 2012, 4:138-146.
16. Cheng P.N., Wheatley D.N. Arginine deprivation addresses the achilles heel of cancer: urea cycle deficiencies in melanoma, HCC and other cancers. Oncol News 2008, 2:6-8.
17. Davis F. Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng 1978, 4:169-173.
18. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
19. Mauldin J.P., Zeinali I., Kleypas K., Woo J.H., Blackwood R.S., Jo C.H., et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl Oncol 2012, 5:26-31.
20. Ramage J., Vallera D.A., Black J., Aplan P., Kees U., Frankel A.E. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res 2003, 27:79-84.
21. Blair A., Hogge D.E., Sutherland H.J. Most acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR-. Blood 1998, 92:4325-4335.
22. Abi-Habib R.J., Liu S., Bugge T., Leppla S.H., Frankel A.E. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004, 104:2143-2148.
23. Kassab E., Darwish M., Timsah Z., Liu S., Leppla S.H., Frankel A.E., et al. Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Transl Oncol 2013, 6:25-32.
24. Kim R.H., Coates J.M., Bowles T.L., McNerney G.P., Sutcliffe J., Jung J.U., et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009, 69:700-708.
25. Agrawal V., Woo J.H., Mauldin J.P., Jo C., Stone E.M., Georgiou G., et al. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental l-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 2012, 23:51-64.
26. Delage B., Fennell D.A., Nicholson L., McNeish I., Lemoine N.R., Crook T., et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010, 126:2762-2772.
27. Agrawal V., Woo J.H., Borthakur G., Kantarjian H., Frankel A.E. Red blood cell-encapsulated l-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 2013, 20:392-402.
28. Periyasamy-Thandavan S., Jiang M., Schoenlein P., Dong Z., Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 2009, 297:244-256.